News

The single-center trial called NeoACT, or P07-1 has started enrolling approximately 40 patients. NeoACT is the first of two new Phase II trials of Provenge being initiated in

The alliance was initiated in October 2005 and is focused on the discovery, development, and commercialization of RNAi therapeutics toward a defined number of Novartis-selected disease gene targets.

Under the terms of the agreement, Smiths Medical will provide its Medfusion Syringe Infusion System and CADD Ambulatory Infusion Systems to HealthTrust’s over 1,400 acute care hospitals and

The license grants Medarex non-exclusive rights to research, develop and commercialize therapeutic antibodies based on Complegent technology for an undisclosed number of targets. In return, BioWa will receive

Under the terms of the settlement, Wyeth has granted Impax a license that would permit Impax to launch its capsule formulation of Effexor XR on or after June

MediGene therefore acquires an exclusive worldwide license for the application and commercialization of Anti L1 antibodies in anti-tumor therapy. In June 2006, MediGene and the German Cancer Research

BioMarin will receive a milestone payment of $1.5 million for this marketing approval along with double-digit royalties on net sales of Biopten for phenylketonuria (PKU) in Japan under

The Attract-2 trial will be conducted by Antisoma’s partner, Novartis, and will evaluate ASA404 as a second-line treatment for non-small cell lung cancer (NSCLC). A separate, ongoing phase

Sciele Pharma is working closely with Summers Laboratories and the FDA to provide additional information that was requested.